Logo

Moderna to Initiate P-III Study of its mRNA-1273 Against COVID-19 in July 2020

Share this

Moderna to Initiate P-III Study of its mRNA-1273 Against COVID-19 in July 2020

Shots:

  • The P-III study will evaluate mRNA-1273 vs PBO in a ratio (1:1) and is expected to enroll ~30-000 patients in the US- to be conducted in collaboration with NIAID. The 1EP of P-III study will be the prevention of symptomatic COVID-19 while 2EP include prevention of severe COVID-19
  • The company has finalized 100 μg as a P-III dose based on the results of P-I study. Moderna will deliver ~500M doses/ year or may ramp up to ~1B doses/ year under a manufacturing agreement with Lonza and is expected to be initiated in 2021
  • BARDA has supported the planning for the P-II and P-III studies of mRNA-1273 as well as the manufacturing scale-up of mRNA-1273. In P-II study- the company has completed the r enrollment of younger adults (n=300) and the sentinel group of older adults (n=50)

Click here to read full press release/ article | Ref: Moderna | Image: Moderna

Related News: Moderna Signs a Ten-Year Worldwide Agreement with Lonza to Manufacture mRNA-1273 Against COVID-19


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions